Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp Alfa Combined With Famitinib and AG-Chemotherapy in Unresectable Pancreatic Cancer
NCT07814859Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa, famitinib in pancreatic ductal adenocarcinoma (PDAC), sponsored by The First Affiliated Hospital of Zhengzhou University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfafamitinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07814859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07814859.